Big money and big data are killing the markets for the retail investor. Write your representatives in congress to initiate a tax in sufficient size to remove the manipulators from the markets. Thes manipulators will destroy the markets and possibly the economy. I am out at $24. Best of luck to the longs.
The stock price of ENDP is impossible to forecast. The earnings are great. The stock is selling below book value and we wittnessed a large insider buy on Aug. 11. The time, date and direction of the next move is in control of the manipulators.
All biotech stocks are subject to big risk until new government policies are firmly established. Presently biotech stocks cannot be evaluated.
You can't buy biotech stocks at this time and feel comfortable. It does not seem to matter how much cash flow or earnings are at this time - their future appears to uncertain. The short term outlook is questionable at best. Good luck to the long term holders.
Thanks for your response. Free cash flow is one of the most important measurements of the true worth of a company and that is the main reason I am back in this stock. Good luck on your investment. Jefferies initiated coverage on Horizon Pharma plc (HZNP) this date with an initial rating of “Buy”. Possibly this will help us a little on Monday.
Yahoo indicates earnings estimates at $2.32 and $2.65 for 2016 and 2017. Does anyone have idea what the GAAP estimate is from these same analysts. The shares appear rediculously cheap if these estimates are anywhere near the acctual numbers. All responses appreciated.
I think your dreaming . Obamacare could bve with us for a long time - like it or not.
Although approximately 3700 shares of DEPO traded after hours at $17.58, the very last trade of 100 shares was traded at $17.01 - the lowest trade of the day.
Sentiment: Strong Buy
I like the stock at its present price; however, I see little chance of a buyout at this time.
Sentiment: Strong Buy
They are full of it ! Follow their advice and you will lose your shirt. Their advice is worthless and contradictory within the firm. Buy or sell - but don't follow any advice from these guys.
I don't know whether your information is accurate; however, such action would be an embarrassment to CNBC and might actually be illegal.